Sarepta Shares Plunge Amidst Study Failures and Earnings Challenges
Sarepta Therapeutics' stock plummeted by over a third after reporting mixed Q3 results, including two drug failures and delayed test outcomes, despite strong sales of its gene therapy Elevidys. The company plans to seek traditional FDA approval for Amondys 45 and Vyondys 53, but uncertainties around regulatory and reimbursement issues persist. Meanwhile, sales of Elevidys exceeded expectations, though the outlook remains uncertain amid regulatory and demand challenges.